Urapidil is a sympatholytic antihypertensive drug used primarily in the treatment of hypertensive crises and chronic hypertension. It acts as an α₁-adrenoceptor antagonist, which helps relax blood vessels and lower blood pressure. Additionally, it functions as a 5-HT1A receptor agonist, which further contributes to blood pressure stabilization by modulating serotonin receptors. Urapidil is commonly used intravenously for rapid blood pressure control in emergency settings. While widely used in Europe, it is not currently approved by the U.S. Food and Drug Administration (FDA).
Parent: Piperazine / Urapidil / Fluanisone
Parent: Piperazine / Urapidil / Fluanisone
Like other medications, urapidil can develop impurities during manufacturing and storage that must be monitored to ensure safety and effectiveness. Regulatory bodies like the European Medicines Agency (EMA) set guidelines on permissible impurity levels to ensure patient safety.
When administered intravenously, urapidil typically begins working within 5 to 10 minutes. Its fast action makes it ideal for use in hypertensive emergencies. The effects usually last for 2 to 6 hours, depending on the dose and patient response.
Urapidil acts as an α₁-adrenoceptor antagonist, which causes vasodilation, leading to reduced blood pressure. Additionally, its action as a 5-HT1A receptor agonist helps to stabilize blood pressure without significantly affecting heart rate. This dual mechanism makes it effective in managing acute and chronic hypertension.
Urapidil is often considered a more targeted alternative to phentolamine for the treatment of hypertensive emergencies. While phentolamine is a non-selective alpha-blocker that affects both α₁ and α₂ receptors, urapidil specifically targets α₁ receptors and also activates 5-HT1A receptors, providing a more controlled blood pressure reduction with fewer side effects, such as reflex tachycardia.
No, urapidil is not currently approved by the U.S. Food and Drug Administration (FDA). It is widely used in Europe and other regions for managing hypertension, primarily in emergency settings, and is regulated by agencies like the European Medicines Agency (EMA).
